AI assistant
BIOLIFE SOLUTIONS INC — Director's Dealing 2024
Mar 13, 2024
32106_dirs_2024-03-13_55674b96-ccf0-4e2e-aadd-5845538db6f3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2024-03-08
Reporting Person: DuRoss Amy (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-08 | Common Stock | A | 11264 | — | Acquired | 40643 | Direct |
| 2024-03-12 | Common Stock | S | 6135 | $16.86 | Disposed | 34508 | Direct |
| 2024-03-13 | Common Stock | S | 5065 | $17 | Disposed | 29443 | Direct |
Footnotes
F1: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.60 to $17.11, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.